TECX
Tectonic Therapeutic Inc
NASDAQ · Biotechnology
$24.37
+1.51 (+6.61%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 64.42M | 64.45M | 57.14M |
| Net Income | 9.98M | 8.55M | 7.27M |
| EPS | — | — | — |
| Profit Margin | 15.5% | 13.3% | 12.7% |
| Rev Growth | +22.9% | -2.6% | -4.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 44.75M | 50.98M | 42.72M |
| Total Equity | 256.38M | 293.64M | 295.97M |
| D/E Ratio | 0.17 | 0.17 | 0.14 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 14.26M | 12.01M | 10.46M |
| Free Cash Flow | 6.92M | 8.94M | 6.74M |